We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer.
- Authors
Greiner, Jochen; K¨ufer, Rainer; Reske, Sven N.; Martin, Volker; ¨ohner, Hartmut; Ringhoffer, Mark
- Abstract
The treatment of metastatic prostate cancer patients refractory to androgen withdrawal and docetaxel therapy is currently discouraging and new therapeutic approaches are vastly needed. Here, we report a long-term remission over one year in a 68-year-old patient with metastatic docetaxel-refractory prostate cancer employing low-dose trofosfamide. The patient suffered from distant failure with several bone lesions and lymph node metastases depicted by a (11) C-Choline positron emission tomography/computerized tomography (PET/CT). After initiation of trofosfamide 100 mg taken orally once a day we observed a steadily decreasing PSA value from initial 46.6 down to 2.1 μg/l. The Choline-PET/CT was repeated after 10 months of continuous therapy and demonstrated a partial remission of the bone lesions and a regression of all involved lymph nodes but one. Taken together we found an astonishing and durable activity of the alkylating agent trofosfamide given in a metronomic fashion.We rate the side effects as low and state an excellent therapeutic ratio of this drug in our patient.
- Subjects
PROSTATE cancer; SPONTANEOUS cancer regression; DOCETAXEL; METASTASIS; CHOLINE; POSITRON emission tomography; TOMOGRAPHY
- Publication
Case Reports in Medicine, 2010, p1
- ISSN
1687-9627
- Publication type
Case Study
- DOI
10.1155/2010/395720